China’s top disease expert admits Chinese vaccines are ineffective

China’s number one disease control official just admitted that the vaccines made have low effectiveness.

Gao Fu, the director of the China Centers for Disease Control on April 10 said the Chinese vaccines “don’t have very high protection rates.”

“It’s now under formal consideration whether we should use different vaccines from different technical lines for the immunization process,” Gao said.

A different CDC official, Wang Huaqing, said the development of mRNA-based vaccines is currently in progress.

“The mRNA vaccines developed in our country have also entered the clinical trial stage,” he mentioned.

Currently, in Britain, researchers are looking at combining the Pfizer-BioNTech and the traditional AstraZeneca vaccine.

Vaccines by Sinovac Biotech Ltd. and Sinopharm have already been distributed to 22 countries including the Philippines.

Researchers in Brazil found that the Sinovac product only had a 50.4 percent chance of preventing symptomatic infections, while the Pfizer-BioNTech vaccine is 97 percent effective.

Due to the approval process, the distribution of Chinese vaccines may not happen in the United States, Western Europe, and Japan.

Sinovac spokesman Liu Peicheng said the different levels of effectiveness depending on the respondent’s age, and the strain of the virus among other factors.

China has not approved any foreign vaccines but is considering mRNA vaccines.

“Everyone should consider the benefits mRNA vaccines can bring for humanity.

“We must follow it carefully and not ignore it just because we already have several types of vaccines already,” he said.

Presidential Spokesperson Harry Roque in January was slammed by the public for claiming that the Sinovac vaccine resulted in a 91 percent efficacy rate without providing any proof.

“Lahat ng dini-discuss natin dito sa press briefing natin, kabahagi ng ating communication plan. Kinakalat po ng ating mga kalaban na matakot dapat sa vaccine ng Tsino. Kinakailangan western brands lang,” Roque said during an online briefing, adding that information against the said vaccine came from the opposition.

“Kaya pinakita po natin na ang vaccine, dumaan sa clinical trials sa iba’t ibang bansa. At least 91.5% ang efficiency rate ng Sinovac,” he insisted.